Clinical Trial Update: Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial safety update for RotigotiNe in autosomal dominant polycystic kidney disease, with the study not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Rotigotine (rotigotine)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Kidney Diseases | Phase 2 | Status: NOT_YET_RECRUITING